Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. 2017

Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
Translational Cancer Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Tromso, North Norway.

The tumor proliferation index marker Ki-67 is strongly associated with tumor cell proliferation, growth and progression, and is widely used in routine clinicopathological investigation. Prostate cancer is a complex multifaceted and biologically heterogeneous disease, and overtreatment of localized, low volume indolent tumors, is evident. Here, we aimed to assess Ki-67 expression and related outcomes of 535 patients treated with radical prostatectomy. The percentage of tumor epithelial cells expressing Ki-67 was determined by immunohistochemical assay, both digital image analysis and visual scoring by light microscope were used for quantification. The association of Ki-67 and prostate cancer was evaluated, as well as its prognostic value. There was a positive correlation between high expression of Ki-67 and Gleason score > 7 (p < 0.001) as well as tumor size (≥ 20 mm, p = 0.03). In univariate analyses, a high expression of Ki-67 in tumor epithelium was significantly associated with biochemical failure (BF) (digital scoring, p = 0.014) and (visual scoring, p = 0.004). In the multivariate analyses, a high level of Ki-67 was an independent poor prognostic factor for biochemical failure-free survival (BFFS) (Visual scoring, Ki67, p = 0.012, HR:1.50, CI95% 1.10-2.06). In conclusion, high Ki-67 expression is an independent negative prognostic marker for biochemical failure. Our findings support the role of Ki-67 as a significant, poor prognostic factor for in prostate cancer outcome.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015999 Multivariate Analysis A set of techniques used when variation in several variables are studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables. Analysis, Multivariate,Multivariate Analyses
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D019394 Ki-67 Antigen A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells. Antigen Ki-67,MIB-1 Antigen,Antigen Ki67,Antigen Ki 67,Antigen, Ki-67,Antigen, MIB-1,Ki 67 Antigen,Ki-67, Antigen,Ki67, Antigen,MIB 1 Antigen

Related Publications

Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
March 1997, Annales de pathologie,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
June 2018, Chromosoma,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
April 2019, Clinica chimica acta; international journal of clinical chemistry,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
May 2012, The Journal of laryngology and otology,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
October 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
October 2018, Trends in biochemical sciences,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
July 1998, American journal of clinical pathology,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
June 2018, Diagnostic pathology,
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
November 2021, Current oncology (Toronto, Ont.),
Elin Richardsen, and Sigve Andersen, and Samer Al-Saad, and Mehrdad Rakaee, and Yngve Nordby, and Mona Irene Pedersen, and Nora Ness, and Thea Grindstad, and Ingeborg Movik, and Tom Dønnem, and Roy Bremnes, and Lill-Tove Busund
January 2005, Dakar medical,
Copied contents to your clipboard!